nopa-analysis-memo.docx

1018-00009 · Client 1018 · NOPA & Protest

nopa-analysis-memo.docx DOCUMENT M&A / Corporate

136 / 176 ← → ✕

MEMORANDUM

TO: Leonard Cross, Responsible Partner Sylvia Hartwell, Billing Partner

FROM: Garrett Simmons, Lead Associate Leila Nazari, Working Associate

DATE: October 20, 2023

RE: Analysis of IRS Notice of Proposed Adjustment — Penterra Pharmaceuticals Corp. (EIN: 22-3741856), Tax Years 2017–2020; C&H Matter No. 1018-00009

SUBJECT: Detailed Analysis of NOPA Dated October 12, 2023 — Proposed Adjustments Totaling $380,400,000

Right-click to update Table of Contents

I. Executive Summary

On October 12, 2023, the Internal Revenue Service, Large Business & International Division, Exam Team LB&I-NE-TP-2022-00641, issued a Notice of Proposed Adjustment ("NOPA") to Penterra Pharmaceuticals Corp. ("PPC" or the "Company") for tax years 2017, 2018, 2019, and 2020, proposing net transfer pricing adjustments under Internal Revenue Code ("IRC") § 482 totaling $380,400,000. The NOPA is the culmination of a detailed examination that was opened on May 16, 2022, during which the IRS exam team issued a total of 47 Information Document Requests ("IDRs") between June 2022 and September 2023, all of which were responded to by Calderwood & Harkness LLP ("C&H") on behalf of the Company. The NOPA was prepared with the analytical support of IRS Economist Dr. Alan Washburne and with the legal guidance of IRS Office of Chief Counsel Attorney-Advisor Franklin Rosario, under the supervision of Senior Counsel Donna Hirabayashi.

The NOPA covers three distinct categories of proposed adjustments, which are summarized as follows:

• Cost-sharing arrangement ("CSA") adjustments: $235,010,000 — The IRS proposes to increase Penterra Biopharma International DAC's ("PBI") cost-sharing percentages by approximately 8 to 12 percentage points for each examination year, asserting that PBI's share of reasonably anticipated benefits ("RAB") was understated.

• Legacy IP royalty rate adjustments: $188,040,000 — The IRS proposes to increase the royalty rate on PBI's license of pre-2012 vintage compounds from 4.5% to 11.0% of non-Americas net sales, relying on a comparable uncontrolled transaction ("CUT") analysis that the IRS contends supports higher arm's-length royalty rates.

• Correlative offset allowed by exam to avoid double-counting: ($42,650,000) — The exam team has allowed a correlative offset to avoid the double attribution of income that would result from simultaneously increasing both the cost-sharing ratio and the royalty rate.

• Net proposed adjustment: $380,400,000

In addition to the income adjustments, the IRS has asserted a 20% substantial valuation misstatement penalty under IRC § 6662(e) on the tax attributable to the aggregate adjustment. Applying the 21% corporate tax rate to the $380.4 million net adjustment yields approximately $79.88 million in proposed tax, and the 20% penalty thereon amounts to approximately $15,977,000 (approximately $15.98 million). The IRS reserved, but did not assert, the 40% gross valuation misstatement penalty under IRC § 6662(h).

This memorandum serves the following purposes: (a) it summarizes each component of the proposed adjustments in detail; (b) it analyzes the IRS's legal and economic positions underlying each adjustment category; (c) it identifies the principal vulnerabilities in the IRS's arguments on both legal and factual grounds; and (d) it provides preliminary recommendations for the defense posture in the Protest to be filed in response to the anticipated 30-Day Letter and any subsequent proceedings before the IRS Office of Appeals. In addition, this memorandum addresses related considerations, including the proposed penalty, the financial reporting implications under ASC 740-10 (FIN 48), the interaction of the proposed adjustments with GILTI and BEAT computations, credit facility covenant issues, SEC disclosure considerations, and coordination with third-party advisors.

The 30-Day Letter is anticipated imminently and was subsequently issued on November 8, 2023. We recommend that the Company promptly prepare to file a comprehensive Protest contesting all proposed adjustments in full, supported by detailed legal and economic analyses.

II. Background

A. Penterra's Corporate Structure and IP Arrangement

Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation that is publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA." PPC's principal executive offices are located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. For fiscal year 2020, PPC reported consolidated revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. The Company employs approximately 14,500 individuals worldwide across its research, development, manufacturing, and commercial operations. PPC's senior leadership includes Chief Executive Officer Catherine Falk, Chief Financial Officer Rajesh Iyer, General Counsel Deborah Staines, and Vice President of Global Tax Marcus Whitfield. PPC's operations span oncology, immunology, and rare disease therapeutic areas, with a pipeline of both proprietary and in-licensed compounds at various stages of clinical development and commercialization.

Penterra Biopharma International DAC ("PBI") is an Irish Designated Activity Company that was incorporated on March 15, 2012, and is registered at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI serves as the IP-holding company and principal entity for the commercialization of PPC's pharmaceutical products outside the Americas (defined as North America, Central America, South America, and the Caribbean). PBI's Managing Director is Aidan Naughton, who has served in that capacity since PBI's establishment and who exercises substantive decision-making authority over PBI's commercial, regulatory, and strategic operations. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI's headcount grew from 52 employees at its establishment in 2012 to 185 employees as of fiscal year 2020, reflecting the Company's progressive build-out of PBI's operational capabilities in Dublin. PBI's Irish effective tax rate is 12.5% on trading income, with qualifying income eligible for the 6.25% rate under Ireland's Knowledge Development box regime (effective from fiscal year 2016). PBI's Irish tax advisor is the Dublin-based firm Thornbury & Keogh (engagement partner Ciarán Thornbury), and PBI maintains its principal Irish banking relationship with Glenmore Bank Ireland plc.

Penterra Holdings Luxembourg S.à r.l. ("PHL") is an intermediate holding company organized as a société à responsabilité limitée under the laws of Luxembourg, with its registered office at 14, rue Aldringen, L-1118 Luxembourg (RCS No. B 168452). PHL is the 100% owner of PBI and is itself 100% owned by PPC. For U.S. federal income tax purposes, PHL is treated as a disregarded entity, such that PBI is treated as a direct subsidiary of PPC for purposes of the transfer pricing analysis and the § 482 adjustments at issue.

Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company (Companies Registration Office No. 512347) located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI operates as a contract manufacturer of oncology and immunology biologics for non-Americas markets under a cost-plus arrangement with PBI, earning a cost-plus-8% markup on its manufacturing activities. PMI employs approximately 620 individuals at its Cork manufacturing facility and is a wholly-owned subsidiary within the Penterra group. PMI is not itself a subject of the NOPA adjustments, but its manufacturing arrangement with PBI is part of the broader transfer pricing structure that the IRS has examined.

B. The Cost-Sharing Arrangement and Legacy IP License

The cost-sharing arrangement at the center of the IRS's proposed adjustments was entered into effective July 1, 2012, between PPC and PBI (through PHL, as disregarded). Under the CSA, PBI acquired the right to develop and exploit PPC's existing and future pharmaceutical IP portfolio outside the Americas territory, in exchange for (i) a platform contribution transaction ("PCT") payment representing the buy-in consideration for pre-existing IP, and (ii) ongoing cost-sharing payments proportional to PBI's reasonably anticipated benefits from the covered intangibles.

PCT Payment. As consideration for PBI's buy-in to PPC's pre-existing IP portfolio — which at the time consisted primarily of clinical-stage and approved oncology compounds, including the then-recently approved Veritaxol — PBI made a lump-sum PCT payment of $312,000,000 to PPC on July 1, 2012. This amount was determined on the basis of a discounted cash flow ("DCF") analysis performed by PPC's transfer pricing advisors at the time, which utilized a weighted average cost of capital ("WACC") of 9.8% and revenue projections based on the Company's contemporaneous product forecasts and market assessments. As discussed in greater detail in Section III.A below, the IRS's economist, Dr. Alan Washburne, has challenged this valuation, asserting that the PCT should have been valued at $852,000,000 using a lower WACC of 7.2% and higher revenue growth assumptions.

Cost-Sharing Ratios. For the examination years 2017 through 2020, PBI's share of annual qualified R&D costs under the CSA was determined based on the parties' respective RAB shares, updated annually in accordance with the CSA agreement and Treas. Reg. § 1.482-7. The cost-sharing ratios and corresponding cost-sharing payments for each examination year were as follows:

The gradual increase in PBI's cost-sharing percentage from 38.2% to 42.7% over the four-year period reflects the growing contribution of non-Americas markets to total anticipated benefits as the Company expanded its commercial presence in EMEA and APAC territories. The cost-sharing percentages were determined prospectively each year on the basis of the best available information regarding anticipated future benefits, consistent with the requirements of Treas. Reg. § 1.482-7(e)(2)(ii).

Legacy IP License Agreement. Separate and apart from the CSA, PBI licensed from PPC a portfolio of pre-2012 vintage compounds — i.e., compounds whose development was substantially complete prior to the effective date of the CSA and which were therefore not covered by the cost-sharing arrangement. Under this license agreement, PBI paid a royalty rate of 4.5% of net sales for the non-Americas territory. The legacy compound portfolio consisted primarily of mature products in the later stages of their commercial lifecycle, with declining sales trajectories over the examination period. The legacy compound non-Americas net sales and royalties paid by PBI to PPC for each examination year were as follows:

The declining trajectory of legacy compound net sales — from $814.6 million in 2017 to $624.1 million in 2020, representing a cumulative decline of approximately 23.4% — reflects the natural lifecycle maturation of these products as they face generic competition and formulary changes in various country markets.

Key Products. PPC's principal products include the following:

• Veritaxol (oncology): PPC's blockbuster oncology product, with 2020 global net sales of approximately $3.12 billion, of which approximately $1.34 billion was attributable to non-Americas markets.

• Imvara (immunology): PPC's leading immunology product, with 2020 global net sales of approximately $1.87 billion, of which approximately $0.79 billion was attributable to non-Americas markets.

• Cerulon (rare disease): PPC's rare disease product, with 2020 global net sales of approximately $0.62 billion, of which approximately $0.28 billion was attributable to non-Americas markets.

C. PBI's Functions, Assets, and Risks

A central issue in the IRS's proposed adjustments — and a critical element of PPC's defense — is the scope and substance of PBI's operations in Ireland. The factual record compiled during the examination establishes that PBI is a substantial operating entity performing meaningful functions, bearing significant risks, and deploying valuable assets in connection with the commercialization of PPC's products outside the Americas.

PBI employed 185 individuals as of fiscal year 2020, a significant increase from the 52 employees at the entity's establishment in 2012. These employees are organized across several functional areas, including regulatory affairs, medical affairs, commercial strategy, and supply chain management, all of which are headquartered at PBI's Dublin offices. PBI maintains approximately 18,000 square feet of office space at Sandyford Business Park in Dublin, which houses its management, regulatory, commercial, and administrative personnel.

PBI's board of directors held a total of 42 board meetings in Dublin over the four-year period from 2017 through 2020, consisting of regular quarterly meetings plus special sessions convened to address significant commercial, regulatory, and strategic matters. Minutes and supporting materials from these meetings document key decisions made by PBI's board and management on matters including pricing strategy, market entry and withdrawal decisions, selection of distribution partners, regulatory submission strategies, and capital allocation for commercial activities across 68 country markets in the EMEA and APAC regions.

PBI bore market risk for non-Americas territories, including the risk of adverse regulatory outcomes, unfavorable pricing and reimbursement decisions, currency fluctuations, and competitive dynamics in its territory markets. PBI made independent pricing decisions across 68 country markets, exercising pricing authority through its commercial strategy team under the direction of Managing Director Aidan Naughton and the PBI board. PBI's cumulative regulatory expenditures for the period 2017 through 2020 totaled approximately €47,200,000, reflecting the substantial cost of preparing and filing regulatory submissions across multiple jurisdictions with varying approval requirements and timelines.

PBI also managed contract manufacturing and distribution arrangements across EMEA and APAC, including the cost-plus manufacturing arrangement with PMI in Cork and logistics and distribution agreements with third-party providers in various country markets.

D. Contemporaneous Transfer Pricing Documentation

PPC maintained contemporaneous transfer pricing documentation for all four examination tax years (2017, 2018, 2019, and 2020), which was originally prepared by Crestfield & Associates LLP, PPC's accounting firm. The engagement partner for the transfer pricing documentation was Martin Ogilvy, CPA, and the transfer pricing partner was Susan Lam, CPA. The documentation was prepared in accordance with the standards set forth in IRC § 6662(e) and the applicable Treasury Regulations, with the specific objective of establishing penalty protection under IRC § 6662(e)(3)(B).

The contemporaneous documentation established the transfer pricing methodology for the CSA in accordance with Treas. Reg. § 1.482-7, including the determination of the cost-sharing ratios based on reasonably anticipated benefits and the valuation of the platform contribution transaction. The documentation also established the royalty rate methodology for the legacy IP license in accordance with Treas. Reg. § 1.482-4, utilizing a CUT analysis to determine an arm's-length royalty rate. In each year, the documentation was prepared before the filing of the applicable tax return and was maintained in a form that could be provided to the IRS upon request.

The documentation was provided to the IRS exam team in response to IDR No. 3 (issued July 12, 2022) and supplemental documentation was provided in response to subsequent IDRs throughout the examination.

E. Procedural History of the Examination

The procedural history of the IRS examination is summarized below, with key dates and milestones:

• May 16, 2022: IRS examination opened via Letter 2205-A, notifying PPC that its federal income tax returns for tax years 2017 through 2020 were under examination by the Large Business & International Division, with a specific focus on international and transfer pricing issues.

• June 2, 2022: PPC engaged Calderwood & Harkness LLP as outside tax counsel to represent the Company in the examination and any related proceedings.

• June 8, 2022: IRS Form 2848 (Power of Attorney and Declaration of Representative) was filed with the IRS, authorizing Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari of Calderwood & Harkness LLP to represent PPC before the IRS in connection with the examination.

• June 20, 2022: A Kovel letter was executed with Whitmore Valuation Group LLC (reference number 1018-00009-KV) to ensure that all economic analyses and valuation work performed by Whitmore in connection with the engagement would be protected by the attorney-client privilege and work-product doctrine, as the work was being performed at the direction of C&H in anticipation of litigation.

• June 2022 – September 2023: The IRS exam team issued a total of 47 IDRs covering a broad range of topics, including transfer pricing documentation, financial data, organizational charts, functional analyses, intercompany agreements, board minutes, employee interviews, R&D cost allocations, product revenue data, and comparable company analyses. All 47 IDRs were responded to by C&H on behalf of PPC within the agreed-upon timeframes.

• October 12, 2023: The IRS issued the NOPA for all four examination tax years, proposing the adjustments that are the subject of this memorandum.

The IRS examination team consisted of Supervisory Revenue Agent Gerald Meskill (Team Manager), Lead Revenue Agent Patricia Dunleavy, IRS Economist Dr. Alan Washburne, and IRS Office of Chief Counsel Attorney-Advisor Franklin Rosario, with oversight from Senior Counsel Donna Hirabayashi. The team's composition — including an economist and Chief Counsel representation — reflects the significance of the case and the complexity of the transfer pricing issues involved.

III. Detailed Analysis of NOPA Proposed Adjustments

A. Adjustment Category 1: CSA Cost-Sharing Ratio — $235,010,000

1. IRS Position

The first and largest category of proposed adjustments relates to the CSA cost-sharing ratios for tax years 2017 through 2020. The IRS asserts that PBI's cost-sharing percentages, as determined by PPC's contemporaneous documentation, understated PBI's share of reasonably anticipated benefits from the covered intangibles, thereby understating PPC's U.S.-source income under the CSA and resulting in an under-allocation of income to PPC.

The IRS proposes increasing PBI's cost-sharing percentage by approximately 8 to 12 percentage points for each examination year, as set forth below:

The IRS's rationale for the proposed increases rests on two primary contentions. First, the IRS contends that PPC's projections of reasonably anticipated benefits understated the value of U.S.-source contributions and overstated the proportionate share of benefits attributable to PBI's non-Americas territory. Dr. Washburne utilized higher revenue growth projections for PBI's non-Americas territory and lower discount rates in his RAB analysis, which had the effect of inflating the anticipated benefit shares attributable to PBI and correspondingly reducing the shares attributable to PPC. In the IRS's view, PBI should have been responsible for a larger share of the R&D costs because it was projected to (and did, in fact) derive a larger share of the benefits from the covered intangibles than was reflected in PPC's contemporaneous cost-sharing calculations.

Second, the IRS argues that the $312 million PCT payment made by PBI to PPC on July 1, 2012, materially undervalued the pre-existing IP contributed by PPC to the CSA. Dr. Washburne valued the PCT at $852,000,000 using an income method with a 7.2% WACC and higher (and, as we discuss below, hindsight-informed) revenue projections, yielding a valuation delta of approximately $540 million relative to the $312 million actually paid. Although tax year 2012 is outside the current examination period (2017–2020), the IRS has used this asserted undervaluation as a basis to adjust the ongoing cost-sharing ratios for the examination years, contending that the ratios fail to reflect the full value of the IP contributed by PPC. In essence, the IRS's theory is that because PPC's pre-existing IP was more valuable than reflected in the PCT payment, PBI has been systematically underpaying for its share of the CSA benefits throughout the period, and the cost-sharing ratios should be adjusted upward to correct for this ongoing distortion.

2. Legal Framework

The legal framework governing the CSA adjustments implicates several provisions of the Internal Revenue Code and Treasury Regulations:

IRC § 482 authorizes the Secretary to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, if the Secretary determines that such distribution, apportionment, or allocation is necessary to prevent evasion of taxes or to clearly reflect the income of any such organizations. Section 482 is the foundational authority for all transfer pricing adjustments and requires that controlled transactions be consistent with an arm's-length standard — that is, the results of controlled transactions must be consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances.

Treas. Reg. § 1.482-7 sets forth the requirements for qualified cost-sharing arrangements, including the methodology for determining reasonably anticipated benefits, the valuation of platform contribution transactions, and the periodic adjustment provisions. Of particular relevance to the current dispute are the following regulatory provisions:

• Treas. Reg. § 1.482-7(e)(2)(ii) — Reasonably anticipated benefits must be measured on a prospective basis, using the best information available at the time the CSA is entered into (and, for ongoing cost-sharing determinations, at the time the ratios are established for each year). This provision is central to PPC's defense against the IRS's use of hindsight-informed projections.

• Treas. Reg. § 1.482-7(g) — Methods for determining the arm's-length charge for a platform contribution transaction, including the income method, acquisition price method, market capitalization method, and residual profit split method.

• Treas. Reg. § 1.482-7(i)(6) — Periodic adjustment provisions, which may permit the IRS to retroactively adjust cost-sharing ratios based on discrepancies between actual and projected outcomes, subject to certain thresholds and conditions.

Treas. Reg. § 1.482-1(d) sets forth the arm's-length standard and provides guidance on the application of the best method rule, comparability analysis, and the arm's-length range.

The periodic adjustment provisions under Treas. Reg. § 1.482-7(i)(6) are of particular concern in this context. These provisions permit the Commissioner to make periodic adjustments to PCT payments (and, by extension, to cost-sharing arrangements) if the actual results of the CSA deviate significantly from the projected results on which the original terms were based. The IRS may invoke these provisions to argue that the actual commercial success of PBI's non-Americas operations exceeded the projections used to set the cost-sharing ratios, justifying an upward adjustment. However, as discussed below, the application of these provisions is subject to significant limitations and must be distinguished from a wholesale recharacterization of the cost-sharing ratios based on hindsight.

3. Analysis of IRS Vulnerabilities — CSA Adjustments

Our analysis identifies several significant vulnerabilities in the IRS's position on the CSA cost-sharing adjustments, each of which should be developed in the Protest and any subsequent Appeals proceedings.

Reasonably Anticipated Benefits Methodology and Hindsight Bias. The most fundamental vulnerability in the IRS's CSA position is the apparent use of hindsight-informed revenue projections in the computation of PBI's RAB share. PPC's cost-sharing ratios were determined prospectively each year on the basis of the best information available at the time, consistent with the express requirements of Treas. Reg. § 1.482-7(e)(2)(ii). PPC's projections were contemporaneously prepared by the Company's finance and commercial operations teams, reviewed by PPC's transfer pricing advisors at Crestfield & Associates, and documented in PPC's contemporaneous transfer pricing reports.

By contrast, Dr. Washburne's analysis appears to incorporate actual realized revenues in computing the RAB shares attributed to PBI for the examination years. The use of actual outcomes to determine what were supposed to be prospective, forward-looking projections is fundamentally inconsistent with the regulatory framework. The regulations require that RAB be measured on the basis of "reasonably anticipated" benefits — not actual, realized benefits. If the IRS were permitted to use hindsight to adjust cost-sharing ratios after the fact, the prospective requirement of the regulations would be rendered meaningless, as any deviation between projected and actual outcomes could be used as a basis for adjustment. This position finds support in Altera Corp. v. Commissioner, 145 T.C. 91 (2015), aff'd, 926 F.3d 1061 (9th Cir. 2019) (addressing the standards for cost-sharing arrangements), and the broader principle that the arm's-length standard evaluates transactions based on the information and circumstances available to the parties at the time of the transaction.

The Protest should include a detailed comparison of PPC's contemporaneous projections with the projections used by Dr. Washburne, identifying each point of divergence and demonstrating that the differences reflect the incorporation of hindsight data rather than legitimate methodological disagreements.

PCT Valuation Relevance and WACC Dispute. The IRS's attempt to bootstrap a 2012 PCT undervaluation — for a transaction that occurred outside the examination years — into adjustments of the 2017–2020 cost-sharing ratios is legally vulnerable on multiple grounds. As an initial matter, the PCT payment of $312 million was contemporaneously determined and documented using an income method/DCF approach with a WACC of 9.8%, which reflects the substantial development and regulatory risk associated with pharmaceutical-stage IP. The $312 million payment falls well within the arm's-length range established by Whitmore Valuation Group's independent DCF analysis, which places the arm's-length range for the PCT at $278 million to $361 million.

The IRS's use of a 7.2% WACC is the primary driver of the valuation gap between the IRS's $852 million PCT value and PPC's $312 million payment. The 260-basis-point differential in WACC accounts for the vast majority of the difference between the two valuations. We believe the IRS's 7.2% WACC is unreasonably low for several reasons:

• The pharmaceutical and biotechnology industry is characterized by high development risk, long development timelines, significant regulatory uncertainty, and high rates of clinical failure. Industry-standard cost-of-capital analyses for pharmaceutical companies consistently reflect these risks through higher discount rates. The 7.2% WACC used by Dr. Washburne is more consistent with the cost of capital for mature, diversified companies with stable cash flows — not for pharmaceutical IP with significant remaining development risk.

• Whitmore's analysis of comparable pharmaceutical and biotechnology company WACC estimates as of July 2012 yielded a range of 8.5% to 12.3%, with a median of 10.1%. PPC's 9.8% WACC falls comfortably within this range, while the IRS's 7.2% falls well below the low end.

• The specific compounds included in the PCT — primarily clinical-stage oncology compounds — carried substantial development risk at the time of the buy-in, including the risk of clinical trial failure, regulatory rejection, and competitive displacement. A discount rate that fails to account for these risks will systematically overvalue the IP and inflate the PCT amount.

Furthermore, even if the IRS could establish that the 2012 PCT was undervalued, the nexus between a 2012 undervaluation and 2017–2020 cost-sharing ratio adjustments is attenuated. The cost-sharing ratios for each year are determined independently based on the RAB shares for that year, and the appropriate remedy for a PCT undervaluation would be an adjustment to the PCT itself — not a wholesale recalibration of subsequent cost-sharing percentages. The IRS's theory conflates two distinct elements of the CSA framework: the buy-in payment for pre-existing IP and the ongoing cost-sharing payments for current R&D. These are separate analytical exercises under the regulations, and the IRS should not be permitted to use an alleged PCT undervaluation as a lever to increase cost-sharing ratios that are otherwise independently determined and arm's-length.

IRS's Proposed Percentages Are Facially Unreasonable. At the proposed cost-sharing percentages of 48.2% to 53.7%, PBI's cost-sharing ratio would significantly exceed the territory's share of actual realized revenue during the examination period. PBI's non-Americas territory accounted for approximately 38% to 43% of PPC's total pharmaceutical revenue during 2017–2020. By proposing cost-sharing ratios that materially exceed PBI's actual revenue share, the IRS's position implies that PBI's non-Americas territory was expected to generate a disproportionately large share of future benefits from the covered IP — a proposition that is inconsistent with the actual commercial trajectory of the products and with the best-available projections at the time the ratios were established.

This internal inconsistency is a significant vulnerability, as it suggests that the IRS's proposed ratios do not, in fact, reflect reasonably anticipated benefits as required by the regulations, but rather represent an arbitrary upward adjustment designed to shift income to the United States.

Whitmore CPM/TNMM Analysis. As an additional check on the reasonableness of the overall transfer pricing outcome, Whitmore Valuation Group performed a Comparable Profits Method / Transactional Net Margin Method ("CPM/TNMM") analysis of PBI's operating margins. The analysis identified 22 comparable distributors and IP-holding companies engaged in pharmaceutical commercialization activities. PBI's operating margins for each of the four examination years fell within the interquartile range of the 22 comparable companies, confirming that PBI's reported profitability is consistent with arm's-length results and that the overall transfer pricing outcome of the CSA is reasonable. This analysis provides a powerful cross-check against the IRS's proposed adjustments and should be prominently featured in the Protest.

B. Adjustment Category 2: Legacy IP Royalty Rate — $188,040,000

1. IRS Position

The second category of proposed adjustments relates to the royalty rate under PBI's license of pre-2012 vintage compounds from PPC. The IRS proposes increasing the royalty rate from 4.5% of net sales to 11.0% of net sales, based on the IRS's analysis of comparable uncontrolled transaction ("CUT") data from third-party pharmaceutical licensing agreements that the IRS contends support a higher arm's-length royalty rate for equivalent-stage, equivalent-therapeutic-area IP.

The proposed additional royalty income to PPC, and the corresponding additional royalty expense to PBI, for each examination year is calculated as follows:

The IRS's proposed 11.0% royalty rate represents a 144% increase over the existing 4.5% rate — from what PPC established as the arm's-length rate to a rate that is materially higher than the upper end of the interquartile range identified by Whitmore's CUT analysis. The IRS's position, if sustained, would have a significant impact on PPC's U.S. taxable income, notwithstanding that the legacy compound net sales are declining over the period, reflecting the natural lifecycle maturation of these products as they face generic competition, formulary changes, and loss of exclusivity in various non-Americas markets.

2. Legal Framework

The legal framework governing the royalty rate adjustments is set forth principally in the following regulatory provisions:

Treas. Reg. § 1.482-4 provides methods for determining the arm's-length consideration for the transfer of intangible property (or the use of intangible property through a license), including the comparable uncontrolled transaction method, the comparable profits method, and the profit split method.

Treas. Reg. § 1.482-4(c) sets forth the requirements for the CUT method, which determines the arm's-length royalty by reference to royalties charged in comparable uncontrolled transactions. The regulation requires a high degree of comparability between the controlled transaction and the uncontrolled comparables, taking into account the following factors: (i) the comparability of the intangible property involved, including its stage of development, uniqueness, and expected profitability; (ii) the comparability of the contractual terms, including territorial scope, exclusivity, duration, and risk allocation; (iii) the comparability of the economic conditions, including market size, competitive environment, and regulatory landscape; and (iv) the comparability of the property or services involved, including the nature of the products being commercialized.

Treas. Reg. § 1.482-1(c) sets forth the best method rule, which requires that the arm's-length result be determined using the method that, under the facts and circumstances of the case, provides the most reliable measure of an arm's-length result. The selection of a method and the application of that method must be based on a thorough analysis of the relevant facts and circumstances, and the method that provides the most reliable result will depend on the degree of comparability between the controlled and uncontrolled transactions and the quality of the data and assumptions used in the analysis.

3. Analysis of IRS Vulnerabilities — Royalty Rate Adjustments

Our analysis identifies several critical vulnerabilities in the IRS's royalty rate position, which collectively present a strong basis for contesting the proposed adjustment.

IRS CUT Selection Criteria Are Overly Aggressive. The IRS's CUT analysis relies on a set of comparable license agreements that, upon initial review, appear to involve early-stage, high-risk IP with significant remaining development costs, broader territorial grants, and materially different risk profiles from the PPC-PBI legacy compound license. The IRS's selected comparables appear to include agreements for compounds that were at earlier stages of clinical development (Phase II or early Phase III) at the time of licensing, with correspondingly higher royalty rates reflecting the licensor's contribution of high-value, high-risk IP with substantial upside potential. By contrast, PPC's legacy compounds are mature, late-lifecycle products with declining sales, limited remaining patent life, and comparatively modest growth prospects. The IRS's failure to adequately account for these differences in selecting and adjusting its CUT set is a fundamental methodological deficiency.

The IRS's proposed 11.0% royalty rate is far above the median and upper quartile of the arm's-length range established by Whitmore's more rigorous CUT analysis. Specifically, the 11.0% rate is approximately 420 basis points above the upper end of the interquartile range (6.8%) identified by Whitmore, placing it well outside the range of arm's-length results.

Whitmore CUT Analysis Results. Whitmore Valuation Group identified 14 comparable uncontrolled pharmaceutical license agreements through a systematic search and screening process that evaluated potential comparables for consistency with the characteristics of the PPC-PBI legacy compound license. The 14 agreements involved the licensing of mature, post-approval pharmaceutical compounds in therapeutic areas comparable to PPC's legacy portfolio, with territorial scope and risk allocations broadly consistent with the PPC-PBI arrangement. The results of Whitmore's CUT analysis are as follows:

• Interquartile range of royalty rates: 3.1% to 6.8%

• Median royalty rate: 4.4%

• PPC's contractual royalty rate: 4.5%

PPC's 4.5% royalty rate falls squarely within the arm's-length interquartile range and is essentially at the median of the 14 comparable agreements. This result powerfully supports the arm's-length character of PPC's royalty rate and demonstrates that the IRS's proposed 11.0% rate is a significant outlier relative to the market evidence.

Declining Sales Trajectory. The legacy compounds subject to the royalty arrangement are mature products with declining non-Americas net sales. Over the examination period, legacy compound net sales declined from $814.6 million in 2017 to $624.1 million in 2020, a cumulative decline of approximately 23.4%. In arm's-length negotiations, licensees of declining-revenue IP would be expected to demand lower royalty rates — not higher rates — to reflect the diminished economic value and remaining useful life of the licensed intangibles. The IRS's proposed upward adjustment from 4.5% to 11.0% is contrary to the economic logic of arm's-length licensing, where royalty rates are inversely correlated with the maturity and declining revenue trajectory of the licensed IP.

This argument is particularly compelling in the context of what arm's-length parties would actually negotiate. An unrelated licensee paying 4.5% on declining-revenue products would have no rational economic basis for agreeing to a rate of 11.0% — such a rate would dramatically reduce the licensee's profitability and, in many cases, render the licensed products commercially unviable in the non-Americas territory. The IRS's proposed rate implies a level of economic return to the licensor that is inconsistent with the economics of mature, declining pharmaceutical products.

Comparability Adjustments Not Made by the IRS. The NOPA and Dr. Washburne's supporting analysis do not appear to include sufficient comparability adjustments to account for the material differences between the IRS's selected CUT agreements and the PPC-PBI legacy compound license. Under Treas. Reg. § 1.482-4(c)(2), comparability adjustments are required when there are material differences between the controlled and uncontrolled transactions that could affect the royalty rate. At a minimum, the IRS's analysis should have adjusted for the following factors:

• Product lifecycle stage: The IRS's CUT agreements appear to involve earlier-stage, higher-risk compounds with greater upside potential, while PPC's legacy compounds are mature products with declining sales and limited remaining useful life.

• Territorial scope: Several of the IRS's CUT agreements appear to involve broader territorial grants (e.g., worldwide or worldwide-ex-U.S.) than the PPC-PBI license, which covers only non-Americas territories.

• Exclusivity terms: Differences in exclusivity provisions, co-promotion rights, and termination provisions can significantly affect royalty rates and must be accounted for in a CUT analysis.

• Risk allocation: The allocation of development risk, regulatory risk, and commercialization risk between licensor and licensee varies across the CUT agreements and differs from the risk allocation in the PPC-PBI arrangement, where PBI bears the full commercial risk for the non-Americas territory.

The absence of adequate comparability adjustments renders the IRS's CUT analysis unreliable under the best method rule and provides a strong basis for challenging the proposed royalty rate adjustment.

C. Correlative Offset — ($42,650,000)

The IRS exam team allowed a correlative offset of $42,650,000 against the aggregate proposed adjustments to avoid double-counting between the CSA cost-sharing adjustment and the royalty rate adjustment. The necessity for a correlative offset arises because certain R&D costs covered by the CSA relate to IP that is also the subject of the legacy royalty arrangement. Increasing both the cost-sharing ratio (which increases PBI's share of R&D costs, thereby increasing PPC's net income from the CSA) and the royalty rate (which increases PPC's royalty income from the legacy license) without an offset would attribute the same economic income to PPC twice — once through the higher cost-sharing ratio and again through the higher royalty rate.

The exam team's calculation of the $42,650,000 offset has not been fully explained in the NOPA, and the workpapers supporting the computation have not yet been provided. Our preliminary analysis suggests that the $42,650,000 correlative offset may be inadequate — that is, it may understate the true overlap between the two adjustment categories. The degree of overlap depends on the extent to which the legacy compounds' R&D costs are included in the CSA's qualified cost pool and the extent to which the value attributed to these compounds is reflected in both the cost-sharing ratios and the royalty rate. If the overlap is larger than the IRS has assumed, a greater offset should be allowed.

Under Treas. Reg. § 1.482-1(g), the IRS is required to take into account the effect of any allocation under § 482 on other related transactions. This provision supports the argument that the correlative offset must be computed with precision to avoid distortive results, and that PPC is entitled to request an increase in the offset if the exam team's computation is shown to be inadequate. We recommend developing a detailed analysis of the appropriate correlative adjustment under Treas. Reg. § 1.482-1(g) for inclusion in the Protest, with supporting calculations from Whitmore Valuation Group demonstrating the true extent of the overlap.

A separate research memorandum on correlative adjustments under Treas. Reg. § 1.482-1(g) will be developed for the Protest.

D. Summary of Net Proposed Adjustments by Year

The following table summarizes the proposed adjustments by year and category. The $42,650,000 correlative offset was allocated by the exam team across the four examination years; however, the precise annual allocation has not been specified in the NOPA. We have estimated the allocation below on a proportional basis, pending confirmation from the exam team or derivation from the NOPA workpapers.

Note: The correlative offset allocations shown above are estimated on a proportional basis and are subject to confirmation. The exact annual allocation will be confirmed with the exam team or derived from the NOPA workpapers when they are provided.

IV. Analysis of IRS Economic Substance Challenge

A. IRS's DEMPE Argument

In addition to the specific transfer pricing adjustments discussed in Section III, the IRS asserted, as a supplemental basis for its proposed adjustments, that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant. The IRS's argument is framed in the language of the OECD's DEMPE framework — Development, Enhancement, Maintenance, Protection, and Exploitation — which provides that the allocation of returns from intangible property should correspond to the functions performed, assets used, and risks assumed by the entities involved in the development and exploitation of the intangibles.

Specifically, the IRS contended that PPC's U.S.-based R&D personnel performed the overwhelming majority of development and enhancement activities related to the covered intangibles, and that PBI's role was limited to routine distribution and commercialization functions that do not warrant the level of IP-related returns that PBI currently earns. The IRS's position, if sustained, would support a recharacterization of PBI as a limited-risk distributor or commissionaire, entitled only to routine returns, rather than as a full-fledged IP owner and entrepreneur bearing market risk and earning residual returns.

The IRS did not present the economic substance argument as a standalone basis for adjustment, but rather as supplemental support for the CSA and royalty adjustments discussed above. Nevertheless, the argument has strategic significance because it could be deployed as leverage in settlement negotiations or at Appeals, and it must be addressed comprehensively in the Protest to prevent it from gaining traction.

B. Assessment of Vulnerabilities in the IRS's Economic Substance Argument

The IRS's economic substance argument is, in our assessment, the weakest of the three positions asserted in the NOPA. The factual record compiled during the examination — including C&H's functional analysis, Whitmore's economic analyses, and the testimony of PBI's employees — overwhelmingly supports PBI's substantive role in the DEMPE spectrum. The key facts supporting PBI's economic substance are as follows:

Personnel and Operational Build-Out. PBI employed 185 individuals as of fiscal year 2020, having grown from 52 employees at its establishment in 2012. The employee base includes personnel in regulatory affairs, medical affairs, commercial strategy, supply chain management, and administrative functions. These are substantive, high-value roles — not routine or ministerial positions — and their growth trajectory demonstrates PBI's progressive build-out of operational capability in Ireland over the period.

Board Governance and Decision-Making. PBI held a total of 42 board meetings in Dublin during the period 2017–2020, consisting of regular quarterly meetings and special sessions. The minutes of these meetings, which were produced in response to IDR No. 14, document key decisions made by PBI's board and management concerning pricing strategy across 68 country markets, market entry and withdrawal decisions, selection and management of distribution partners, regulatory submission strategies, and capital allocation. These decisions were made independently by PBI's leadership, with Managing Director Aidan Naughton exercising substantive decision-making authority.

Independent Pricing Authority. PBI made independent pricing decisions across 68 country markets in the EMEA and APAC regions. These pricing decisions were not dictated by PPC's U.S. headquarters; rather, they were made by PBI's commercial strategy team based on local market conditions, competitive dynamics, regulatory and reimbursement environments, and customer relationships. The independence of PBI's pricing authority is a critical indicator of substantive operational control and entrepreneurial risk-bearing.

Regulatory Expenditures. PBI incurred cumulative regulatory expenditures of approximately €47,200,000 during 2017–2020 for the preparation and filing of regulatory submissions across multiple non-Americas jurisdictions. These expenditures relate to PBI's performance of Maintenance, Protection, and Exploitation functions within the DEMPE framework, as regulatory compliance is essential to maintaining the value and marketability of the licensed intangibles in each country market.

Market Risk. PBI bore market risk for the non-Americas territories, including the risk of adverse regulatory outcomes (e.g., failure to obtain or maintain marketing authorization), unfavorable pricing and reimbursement decisions by government health authorities, currency fluctuations, competitive displacement, and changes in treatment guidelines. PBI's assumption of these risks is a key element of its role as an entrepreneur rather than a limited-risk entity.

Physical Presence and Infrastructure. PBI maintained approximately 18,000 square feet of office space at Sandyford Business Park in Dublin, providing a dedicated physical location for its management, regulatory, commercial, and administrative operations. PBI also maintained independent banking with Glenmore Bank Ireland plc, further demonstrating its operational independence from PPC's U.S. operations.

C&H Functional Analysis and Employee Interviews. C&H prepared a comprehensive functional analysis of PBI in October 2022, which was updated in March 2023 to reflect additional information gathered during the examination. The functional analysis documents PBI's personnel, functions, assets, and risks in detail and concludes that PBI performs substantive DEMPE functions — particularly in the areas of Maintenance, Protection, and Exploitation — that justify its role as IP owner and CSA participant. The functional analysis is supported by the results of 12 key PBI employee interviews conducted in August and September 2022, in which PBI personnel described their roles, responsibilities, and decision-making authority in their own words. The interview testimony corroborates PBI's independent decision-making and substantive operational functions.

Whitmore Economic Analyses. Whitmore Valuation Group's economic analyses — including the CPM/TNMM benchmarking analysis, the CUT analysis, and the DCF valuation of the PCT — are consistent with and support PBI's role as a substantive entity with genuine operational substance. PBI's reported profitability is consistent with that of comparable entities performing similar functions, bearing similar risks, and deploying similar assets, which is a strong indicator that PBI's transfer pricing results reflect its actual economic contribution.

In sum, the IRS's economic substance argument is contradicted by a comprehensive and well-documented factual record. However, the argument should not be dismissed or treated lightly. The IRS may deploy it as leverage in negotiations, and it could resonate with an Appeals officer or, in a worst-case scenario, with a court if the case proceeds to litigation. The Protest should address the economic substance argument comprehensively, presenting the full body of evidence supporting PBI's substantive role and directly rebutting the IRS's characterization of PBI as a routine distribution entity.

V. Analysis of Proposed Penalty — IRC § 6662(e)

A. IRS's Penalty Assertion

The IRS has asserted a 20% substantial valuation misstatement penalty under IRC § 6662(e) on the tax attributable to the $380,400,000 net § 482 allocation. Section 6662(e) imposes a 20% penalty on the portion of an underpayment of tax attributable to a substantial valuation misstatement under Chapter 1, which includes (among other things) any § 482 transfer pricing adjustment that exceeds the applicable thresholds. The NOPA's proposed penalty calculation is as follows:

Net proposed adjustment: $380,400,000 Corporate tax rate: 21% Tax attributable to adjustment: $380,400,000 × 21% = $79,884,000 20% penalty: $79,884,000 × 20% = $15,976,800 (approximately $15,977,000)

The IRS reserved, but did not assert, the 40% gross valuation misstatement penalty under IRC § 6662(h). The reservation of the 40% penalty preserves the IRS's ability to assert the higher penalty at a later stage, although the decision not to assert it in the NOPA may indicate that the exam team does not believe the threshold for a gross valuation misstatement has been met. However, this possibility should be monitored, and PPC's defense strategy should be prepared to address the 40% penalty in the event it is subsequently asserted.

B. Reasonable Cause and Penalty Protection Defense

PPC has a strong basis for contesting the proposed penalty under the reasonable-cause exception of IRC § 6662(e)(3)(B), which provides that no penalty shall be imposed under § 6662(e) with respect to any portion of an underpayment if the taxpayer establishes that there was reasonable cause for, and the taxpayer acted in good faith with respect to, such portion. In the transfer pricing context, the reasonable-cause standard is generally satisfied when the taxpayer maintains contemporaneous documentation that (i) meets the requirements of the applicable regulations and (ii) reflects a reasonable methodology that was applied in good faith.

PPC maintained contemporaneous transfer pricing documentation for all four examination tax years, which was prepared by Crestfield & Associates LLP (transfer pricing partner Susan Lam, CPA) in accordance with the standards of Treas. Reg. § 1.482-7 (for the CSA) and Treas. Reg. § 1.482-4 (for the legacy IP royalty). The documentation was prepared before the filing of each return and reflects a reasonable, good-faith effort to comply with the arm's-length standard. The specific elements supporting PPC's penalty defense include:

• The contemporaneous documentation was prepared by a qualified and experienced transfer pricing firm, using recognized methodologies and reliable data.

• The CSA cost-sharing ratios were determined using a RAB methodology that complies with the requirements of Treas. Reg. § 1.482-7(e)(2), based on prospective projections of future benefits.

• The 4.5% royalty rate for the legacy IP license was established through a CUT analysis that identified 14 comparable uncontrolled pharmaceutical license agreements, and the 4.5% rate falls at the median (4.4%) of the arm's-length interquartile range.

• The PCT was valued using an income method/DCF approach with a 9.8% WACC, which is within the range of industry-standard cost-of-capital estimates for pharmaceutical companies.

• PPC's transfer pricing positions are consistent across all four tax years and reflect a coherent, well-reasoned approach to intercompany pricing that is grounded in established transfer pricing principles.

Our assessment is that the penalty defense is strong. PPC's positions are reasonable and well-documented, even if the IRS disagrees with the specific numerical results. The penalty provisions are not intended to punish taxpayers who take reasonable positions in good faith; rather, they are designed to deter willful or reckless disregard of the arm's-length standard. PPC's conduct in this case falls well outside the scope of the penalty provisions. This argument will be a central element of the Protest and any subsequent Appeals proceeding, and we recommend asserting the reasonable-cause defense vigorously.

C. TCJA Rate Considerations on Penalty Computation

The NOPA appears to apply the 21% corporate tax rate uniformly to all four examination years in computing the tax attributable to the proposed adjustment and the corresponding penalty. However, for tax year 2017 (the period prior to the effective date of the Tax Cuts and Jobs Act of 2017, which reduced the corporate tax rate from 35% to 21% effective January 1, 2018), the applicable corporate tax rate is 35%, not 21%.

If the 35% rate applies to the 2017 adjustment, the tax and penalty allocable to that year would be materially higher than the NOPA reflects:

• Estimated 2017 net adjustment (from table above): approximately $90,280,000

• Tax at 35%: $90,280,000 × 35% = $31,598,000

• Tax at 21%: $90,280,000 × 21% = $18,958,800

• Difference in tax: $31,598,000 − $18,958,800 = $12,639,200

• Additional penalty at 20%: $12,639,200 × 20% = $2,527,840

The application of the correct rate to the 2017 adjustment should be confirmed with the exam team. If the IRS intends to apply the 35% rate to the 2017 adjustment, the overall proposed tax and penalty amounts will increase by the amounts indicated above. This issue does not affect the substantive merits of the adjustment, but it has a significant impact on the financial exposure calculation and should be factored into the FIN 48 analysis and settlement authority assessment.

VI. Assessment of IRS Economist's Methodology (Dr. Alan Washburne)

A. PCT Valuation — Income Method

As discussed in Section III.A above, Dr. Washburne valued the platform contribution transaction at $852,000,000 using an income method with a 7.2% weighted average cost of capital, compared to the $312,000,000 actually paid by PBI on July 1, 2012. The $540 million delta between the IRS's valuation and the actual PCT payment is driven primarily by two factors: (i) the difference in discount rates (7.2% versus 9.8%), and (ii) differences in the revenue projections used in the DCF models.

C&H's independent analysis, performed by Whitmore Valuation Group under the Kovel arrangement (reference 1018-00009-KV), used a 9.8% WACC and the Company's contemporaneous revenue projections to arrive at an arm's-length range of $278 million to $361 million for the PCT, with $312 million falling near the midpoint of this range. The 260-basis-point spread between the IRS's 7.2% WACC and PPC's 9.8% WACC is the key battleground in the PCT valuation dispute, as small differences in discount rates produce large differences in present-value calculations over the long projection horizons involved in pharmaceutical IP valuation.

As discussed in Section III.A.3 above, the IRS's 7.2% WACC is inconsistent with industry-standard cost-of-capital analyses for pharmaceutical and biotechnology companies, which reflect the significant development, regulatory, and commercial risks inherent in pharmaceutical IP. Whitmore's analysis of 18 publicly traded pharmaceutical and biotechnology companies as of July 2012 yielded a WACC range of 8.5% to 12.3%, with a median of 10.1%. The IRS's 7.2% rate falls well below the bottom of this range and is more consistent with the cost of capital for large-cap diversified industrials or utilities — not for pharmaceutical companies with significant pipeline risk.

B. Revenue Projections

Dr. Washburne applied higher revenue growth projections for PBI's non-Americas territory than those used in PPC's contemporaneous analyses. These higher projections had the effect of inflating the RAB shares attributed to PBI and correspondingly increasing the cost-sharing percentages proposed by the IRS. As noted in Section III.A.3, these projections appear to incorporate actual realized revenues — that is, the IRS economist appears to have looked at PBI's actual commercial performance during the examination years and used those outcomes as the basis for computing what PBI's RAB shares "should have been." This approach is fundamentally inconsistent with the prospective requirement of Treas. Reg. § 1.482-7(e)(2)(ii), which requires that reasonably anticipated benefits be measured on the basis of forward-looking projections using the best available information at the time the cost-sharing ratios are established.

The Protest should include a detailed, year-by-year comparison of PPC's contemporaneous revenue projections with the projections used by Dr. Washburne, identifying the specific data points where the IRS's projections diverge from PPC's projections and demonstrating that the divergences are attributable to the incorporation of hindsight data. This analysis should be prepared in coordination with Whitmore Valuation Group and presented in a format that clearly illustrates the improper use of actual outcomes in a prospective analysis.

C. CUT Selection for Royalty Rate

Dr. Washburne's CUT selection for the royalty rate adjustment relied on a set of comparable license agreements that, as discussed in Section III.B.3 above, involved earlier-stage IP with broader territorial scope and different risk profiles from the PPC-PBI legacy compound license. The comparability adjustments applied by Dr. Washburne to his selected CUTs w

PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT This memorandum was prepared by counsel in anticipation of litigation and is protected by the attorney-client privilege and the work-product doctrine. This document should not be disclosed to any person or entity outside of the attorney-client relationship without the prior written consent of Calderwood & Harkness LLP.
MEMORANDUM
TO: Leonard Cross, Responsible Partner Sylvia Hartwell, Billing Partner
FROM: Garrett Simmons, Lead Associate Leila Nazari, Working Associate
DATE: October 20, 2023
RE: Analysis of IRS Notice of Proposed Adjustment — Penterra Pharmaceuticals Corp. (EIN: 22-3741856), Tax Years 2017–2020; C&H Matter No. 1018-00009
SUBJECT: Detailed Analysis of NOPA Dated October 12, 2023 — Proposed Adjustments Totaling $380,400,000
Right-click to update Table of Contents
I. Executive Summary
On October 12, 2023, the Internal Revenue Service, Large Business & International Division, Exam Team LB&I-NE-TP-2022-00641, issued a Notice of Proposed Adjustment ("NOPA") to Penterra Pharmaceuticals Corp. ("PPC" or the "Company") for tax years 2017, 2018, 2019, and 2020, proposing net transfer pricing adjustments under Internal Revenue Code ("IRC") § 482 totaling $380,400,000. The NOPA is the culmination of a detailed examination that was opened on May 16, 2022, during which the IRS exam team issued a total of 47 Information Document Requests ("IDRs") between June 2022 and September 2023, all of which were responded to by Calderwood & Harkness LLP ("C&H") on behalf of the Company. The NOPA was prepared with the analytical support of IRS Economist Dr. Alan Washburne and with the legal guidance of IRS Office of Chief Counsel Attorney-Advisor Franklin Rosario, under the supervision of Senior Counsel Donna Hirabayashi.
The NOPA covers three distinct categories of proposed adjustments, which are summarized as follows:
• Cost-sharing arrangement ("CSA") adjustments: $235,010,000 — The IRS proposes to increase Penterra Biopharma International DAC's ("PBI") cost-sharing percentages by approximately 8 to 12 percentage points for each examination year, asserting that PBI's share of reasonably anticipated benefits ("RAB") was understated.
• Legacy IP royalty rate adjustments: $188,040,000 — The IRS proposes to increase the royalty rate on PBI's license of pre-2012 vintage compounds from 4.5% to 11.0% of non-Americas net sales, relying on a comparable uncontrolled transaction ("CUT") analysis that the IRS contends supports higher arm's-length royalty rates.
• Correlative offset allowed by exam to avoid double-counting: ($42,650,000) — The exam team has allowed a correlative offset to avoid the double attribution of income that would result from simultaneously increasing both the cost-sharing ratio and the royalty rate.
• Net proposed adjustment: $380,400,000
In addition to the income adjustments, the IRS has asserted a 20% substantial valuation misstatement penalty under IRC § 6662(e) on the tax attributable to the aggregate adjustment. Applying the 21% corporate tax rate to the $380.4 million net adjustment yields approximately $79.88 million in proposed tax, and the 20% penalty thereon amounts to approximately $15,977,000 (approximately $15.98 million). The IRS reserved, but did not assert, the 40% gross valuation misstatement penalty under IRC § 6662(h).
This memorandum serves the following purposes: (a) it summarizes each component of the proposed adjustments in detail; (b) it analyzes the IRS's legal and economic positions underlying each adjustment category; (c) it identifies the principal vulnerabilities in the IRS's arguments on both legal and factual grounds; and (d) it provides preliminary recommendations for the defense posture in the Protest to be filed in response to the anticipated 30-Day Letter and any subsequent proceedings before the IRS Office of Appeals. In addition, this memorandum addresses related considerations, including the proposed penalty, the financial reporting implications under ASC 740-10 (FIN 48), the interaction of the proposed adjustments with GILTI and BEAT computations, credit facility covenant issues, SEC disclosure considerations, and coordination with third-party advisors.
The 30-Day Letter is anticipated imminently and was subsequently issued on November 8, 2023. We recommend that the Company promptly prepare to file a comprehensive Protest contesting all proposed adjustments in full, supported by detailed legal and economic analyses.
II. Background
A. Penterra's Corporate Structure and IP Arrangement
Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation that is publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA." PPC's principal executive offices are located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. For fiscal year 2020, PPC reported consolidated revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. The Company employs approximately 14,500 individuals worldwide across its research, development, manufacturing, and commercial operations. PPC's senior leadership includes Chief Executive Officer Catherine Falk, Chief Financial Officer Rajesh Iyer, General Counsel Deborah Staines, and Vice President of Global Tax Marcus Whitfield. PPC's operations span oncology, immunology, and rare disease therapeutic areas, with a pipeline of both proprietary and in-licensed compounds at various stages of clinical development and commercialization.
Penterra Biopharma International DAC ("PBI") is an Irish Designated Activity Company that was incorporated on March 15, 2012, and is registered at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI serves as the IP-holding company and principal entity for the commercialization of PPC's pharmaceutical products outside the Americas (defined as North America, Central America, South America, and the Caribbean). PBI's Managing Director is Aidan Naughton, who has served in that capacity since PBI's establishment and who exercises substantive decision-making authority over PBI's commercial, regulatory, and strategic operations. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI's headcount grew from 52 employees at its establishment in 2012 to 185 employees as of fiscal year 2020, reflecting the Company's progressive build-out of PBI's operational capabilities in Dublin. PBI's Irish effective tax rate is 12.5% on trading income, with qualifying income eligible for the 6.25% rate under Ireland's Knowledge Development box regime (effective from fiscal year 2016). PBI's Irish tax advisor is the Dublin-based firm Thornbury & Keogh (engagement partner Ciarán Thornbury), and PBI maintains its principal Irish banking relationship with Glenmore Bank Ireland plc.
Penterra Holdings Luxembourg S.à r.l. ("PHL") is an intermediate holding company organized as a société à responsabilité limitée under the laws of Luxembourg, with its registered office at 14, rue Aldringen, L-1118 Luxembourg (RCS No. B 168452). PHL is the 100% owner of PBI and is itself 100% owned by PPC. For U.S. federal income tax purposes, PHL is treated as a disregarded entity, such that PBI is treated as a direct subsidiary of PPC for purposes of the transfer pricing analysis and the § 482 adjustments at issue.
Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company (Companies Registration Office No. 512347) located at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI operates as a contract manufacturer of oncology and immunology biologics for non-Americas markets under a cost-plus arrangement with PBI, earning a cost-plus-8% markup on its manufacturing activities. PMI employs approximately 620 individuals at its Cork manufacturing facility and is a wholly-owned subsidiary within the Penterra group. PMI is not itself a subject of the NOPA adjustments, but its manufacturing arrangement with PBI is part of the broader transfer pricing structure that the IRS has examined.
B. The Cost-Sharing Arrangement and Legacy IP License
The cost-sharing arrangement at the center of the IRS's proposed adjustments was entered into effective July 1, 2012, between PPC and PBI (through PHL, as disregarded). Under the CSA, PBI acquired the right to develop and exploit PPC's existing and future pharmaceutical IP portfolio outside the Americas territory, in exchange for (i) a platform contribution transaction ("PCT") payment representing the buy-in consideration for pre-existing IP, and (ii) ongoing cost-sharing payments proportional to PBI's reasonably anticipated benefits from the covered intangibles.
PCT Payment. As consideration for PBI's buy-in to PPC's pre-existing IP portfolio — which at the time consisted primarily of clinical-stage and approved oncology compounds, including the then-recently approved Veritaxol — PBI made a lump-sum PCT payment of $312,000,000 to PPC on July 1, 2012. This amount was determined on the basis of a discounted cash flow ("DCF") analysis performed by PPC's transfer pricing advisors at the time, which utilized a weighted average cost of capital ("WACC") of 9.8% and revenue projections based on the Company's contemporaneous product forecasts and market assessments. As discussed in greater detail in Section III.A below, the IRS's economist, Dr. Alan Washburne, has challenged this valuation, asserting that the PCT should have been valued at $852,000,000 using a lower WACC of 7.2% and higher revenue growth assumptions.
Cost-Sharing Ratios. For the examination years 2017 through 2020, PBI's share of annual qualified R&D costs under the CSA was determined based on the parties' respective RAB shares, updated annually in accordance with the CSA agreement and Treas. Reg. § 1.482-7. The cost-sharing ratios and corresponding cost-sharing payments for each examination year were as follows:
The gradual increase in PBI's cost-sharing percentage from 38.2% to 42.7% over the four-year period reflects the growing contribution of non-Americas markets to total anticipated benefits as the Company expanded its commercial presence in EMEA and APAC territories. The cost-sharing percentages were determined prospectively each year on the basis of the best available information regarding anticipated future benefits, consistent with the requirements of Treas. Reg. § 1.482-7(e)(2)(ii).
Legacy IP License Agreement. Separate and apart from the CSA, PBI licensed from PPC a portfolio of pre-2012 vintage compounds — i.e., compounds whose development was substantially complete prior to the effective date of the CSA and which were therefore not covered by the cost-sharing arrangement. Under this license agreement, PBI paid a royalty rate of 4.5% of net sales for the non-Americas territory. The legacy compound portfolio consisted primarily of mature products in the later stages of their commercial lifecycle, with declining sales trajectories over the examination period. The legacy compound non-Americas net sales and royalties paid by PBI to PPC for each examination year were as follows:
The declining trajectory of legacy compound net sales — from $814.6 million in 2017 to $624.1 million in 2020, representing a cumulative decline of approximately 23.4% — reflects the natural lifecycle maturation of these products as they face generic competition and formulary changes in various country markets.
Key Products. PPC's principal products include the following:
• Veritaxol (oncology): PPC's blockbuster oncology product, with 2020 global net sales of approximately $3.12 billion, of which approximately $1.34 billion was attributable to non-Americas markets.
• Imvara (immunology): PPC's leading immunology product, with 2020 global net sales of approximately $1.87 billion, of which approximately $0.79 billion was attributable to non-Americas markets.
• Cerulon (rare disease): PPC's rare disease product, with 2020 global net sales of approximately $0.62 billion, of which approximately $0.28 billion was attributable to non-Americas markets.
C. PBI's Functions, Assets, and Risks
A central issue in the IRS's proposed adjustments — and a critical element of PPC's defense — is the scope and substance of PBI's operations in Ireland. The factual record compiled during the examination establishes that PBI is a substantial operating entity performing meaningful functions, bearing significant risks, and deploying valuable assets in connection with the commercialization of PPC's products outside the Americas.
PBI employed 185 individuals as of fiscal year 2020, a significant increase from the 52 employees at the entity's establishment in 2012. These employees are organized across several functional areas, including regulatory affairs, medical affairs, commercial strategy, and supply chain management, all of which are headquartered at PBI's Dublin offices. PBI maintains approximately 18,000 square feet of office space at Sandyford Business Park in Dublin, which houses its management, regulatory, commercial, and administrative personnel.
PBI's board of directors held a total of 42 board meetings in Dublin over the four-year period from 2017 through 2020, consisting of regular quarterly meetings plus special sessions convened to address significant commercial, regulatory, and strategic matters. Minutes and supporting materials from these meetings document key decisions made by PBI's board and management on matters including pricing strategy, market entry and withdrawal decisions, selection of distribution partners, regulatory submission strategies, and capital allocation for commercial activities across 68 country markets in the EMEA and APAC regions.
PBI bore market risk for non-Americas territories, including the risk of adverse regulatory outcomes, unfavorable pricing and reimbursement decisions, currency fluctuations, and competitive dynamics in its territory markets. PBI made independent pricing decisions across 68 country markets, exercising pricing authority through its commercial strategy team under the direction of Managing Director Aidan Naughton and the PBI board. PBI's cumulative regulatory expenditures for the period 2017 through 2020 totaled approximately €47,200,000, reflecting the substantial cost of preparing and filing regulatory submissions across multiple jurisdictions with varying approval requirements and timelines.
PBI also managed contract manufacturing and distribution arrangements across EMEA and APAC, including the cost-plus manufacturing arrangement with PMI in Cork and logistics and distribution agreements with third-party providers in various country markets.
D. Contemporaneous Transfer Pricing Documentation
PPC maintained contemporaneous transfer pricing documentation for all four examination tax years (2017, 2018, 2019, and 2020), which was originally prepared by Crestfield & Associates LLP, PPC's accounting firm. The engagement partner for the transfer pricing documentation was Martin Ogilvy, CPA, and the transfer pricing partner was Susan Lam, CPA. The documentation was prepared in accordance with the standards set forth in IRC § 6662(e) and the applicable Treasury Regulations, with the specific objective of establishing penalty protection under IRC § 6662(e)(3)(B).
The contemporaneous documentation established the transfer pricing methodology for the CSA in accordance with Treas. Reg. § 1.482-7, including the determination of the cost-sharing ratios based on reasonably anticipated benefits and the valuation of the platform contribution transaction. The documentation also established the royalty rate methodology for the legacy IP license in accordance with Treas. Reg. § 1.482-4, utilizing a CUT analysis to determine an arm's-length royalty rate. In each year, the documentation was prepared before the filing of the applicable tax return and was maintained in a form that could be provided to the IRS upon request.
The documentation was provided to the IRS exam team in response to IDR No. 3 (issued July 12, 2022) and supplemental documentation was provided in response to subsequent IDRs throughout the examination.
E. Procedural History of the Examination
The procedural history of the IRS examination is summarized below, with key dates and milestones:
• May 16, 2022: IRS examination opened via Letter 2205-A, notifying PPC that its federal income tax returns for tax years 2017 through 2020 were under examination by the Large Business & International Division, with a specific focus on international and transfer pricing issues.
• June 2, 2022: PPC engaged Calderwood & Harkness LLP as outside tax counsel to represent the Company in the examination and any related proceedings.
• June 8, 2022: IRS Form 2848 (Power of Attorney and Declaration of Representative) was filed with the IRS, authorizing Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari of Calderwood & Harkness LLP to represent PPC before the IRS in connection with the examination.
• June 20, 2022: A Kovel letter was executed with Whitmore Valuation Group LLC (reference number 1018-00009-KV) to ensure that all economic analyses and valuation work performed by Whitmore in connection with the engagement would be protected by the attorney-client privilege and work-product doctrine, as the work was being performed at the direction of C&H in anticipation of litigation.
• June 2022 – September 2023: The IRS exam team issued a total of 47 IDRs covering a broad range of topics, including transfer pricing documentation, financial data, organizational charts, functional analyses, intercompany agreements, board minutes, employee interviews, R&D cost allocations, product revenue data, and comparable company analyses. All 47 IDRs were responded to by C&H on behalf of PPC within the agreed-upon timeframes.
• October 12, 2023: The IRS issued the NOPA for all four examination tax years, proposing the adjustments that are the subject of this memorandum.
The IRS examination team consisted of Supervisory Revenue Agent Gerald Meskill (Team Manager), Lead Revenue Agent Patricia Dunleavy, IRS Economist Dr. Alan Washburne, and IRS Office of Chief Counsel Attorney-Advisor Franklin Rosario, with oversight from Senior Counsel Donna Hirabayashi. The team's composition — including an economist and Chief Counsel representation — reflects the significance of the case and the complexity of the transfer pricing issues involved.
III. Detailed Analysis of NOPA Proposed Adjustments
A. Adjustment Category 1: CSA Cost-Sharing Ratio — $235,010,000
1. IRS Position
The first and largest category of proposed adjustments relates to the CSA cost-sharing ratios for tax years 2017 through 2020. The IRS asserts that PBI's cost-sharing percentages, as determined by PPC's contemporaneous documentation, understated PBI's share of reasonably anticipated benefits from the covered intangibles, thereby understating PPC's U.S.-source income under the CSA and resulting in an under-allocation of income to PPC.
The IRS proposes increasing PBI's cost-sharing percentage by approximately 8 to 12 percentage points for each examination year, as set forth below:
The IRS's rationale for the proposed increases rests on two primary contentions. First, the IRS contends that PPC's projections of reasonably anticipated benefits understated the value of U.S.-source contributions and overstated the proportionate share of benefits attributable to PBI's non-Americas territory. Dr. Washburne utilized higher revenue growth projections for PBI's non-Americas territory and lower discount rates in his RAB analysis, which had the effect of inflating the anticipated benefit shares attributable to PBI and correspondingly reducing the shares attributable to PPC. In the IRS's view, PBI should have been responsible for a larger share of the R&D costs because it was projected to (and did, in fact) derive a larger share of the benefits from the covered intangibles than was reflected in PPC's contemporaneous cost-sharing calculations.
Second, the IRS argues that the $312 million PCT payment made by PBI to PPC on July 1, 2012, materially undervalued the pre-existing IP contributed by PPC to the CSA. Dr. Washburne valued the PCT at $852,000,000 using an income method with a 7.2% WACC and higher (and, as we discuss below, hindsight-informed) revenue projections, yielding a valuation delta of approximately $540 million relative to the $312 million actually paid. Although tax year 2012 is outside the current examination period (2017–2020), the IRS has used this asserted undervaluation as a basis to adjust the ongoing cost-sharing ratios for the examination years, contending that the ratios fail to reflect the full value of the IP contributed by PPC. In essence, the IRS's theory is that because PPC's pre-existing IP was more valuable than reflected in the PCT payment, PBI has been systematically underpaying for its share of the CSA benefits throughout the period, and the cost-sharing ratios should be adjusted upward to correct for this ongoing distortion.
2. Legal Framework
The legal framework governing the CSA adjustments implicates several provisions of the Internal Revenue Code and Treasury Regulations:
IRC § 482 authorizes the Secretary to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, if the Secretary determines that such distribution, apportionment, or allocation is necessary to prevent evasion of taxes or to clearly reflect the income of any such organizations. Section 482 is the foundational authority for all transfer pricing adjustments and requires that controlled transactions be consistent with an arm's-length standard — that is, the results of controlled transactions must be consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances.
Treas. Reg. § 1.482-7 sets forth the requirements for qualified cost-sharing arrangements, including the methodology for determining reasonably anticipated benefits, the valuation of platform contribution transactions, and the periodic adjustment provisions. Of particular relevance to the current dispute are the following regulatory provisions:
• Treas. Reg. § 1.482-7(e)(2)(ii) — Reasonably anticipated benefits must be measured on a prospective basis, using the best information available at the time the CSA is entered into (and, for ongoing cost-sharing determinations, at the time the ratios are established for each year). This provision is central to PPC's defense against the IRS's use of hindsight-informed projections.
• Treas. Reg. § 1.482-7(g) — Methods for determining the arm's-length charge for a platform contribution transaction, including the income method, acquisition price method, market capitalization method, and residual profit split method.
• Treas. Reg. § 1.482-7(i)(6) — Periodic adjustment provisions, which may permit the IRS to retroactively adjust cost-sharing ratios based on discrepancies between actual and projected outcomes, subject to certain thresholds and conditions.
Treas. Reg. § 1.482-1(d) sets forth the arm's-length standard and provides guidance on the application of the best method rule, comparability analysis, and the arm's-length range.
The periodic adjustment provisions under Treas. Reg. § 1.482-7(i)(6) are of particular concern in this context. These provisions permit the Commissioner to make periodic adjustments to PCT payments (and, by extension, to cost-sharing arrangements) if the actual results of the CSA deviate significantly from the projected results on which the original terms were based. The IRS may invoke these provisions to argue that the actual commercial success of PBI's non-Americas operations exceeded the projections used to set the cost-sharing ratios, justifying an upward adjustment. However, as discussed below, the application of these provisions is subject to significant limitations and must be distinguished from a wholesale recharacterization of the cost-sharing ratios based on hindsight.
3. Analysis of IRS Vulnerabilities — CSA Adjustments
Our analysis identifies several significant vulnerabilities in the IRS's position on the CSA cost-sharing adjustments, each of which should be developed in the Protest and any subsequent Appeals proceedings.
Reasonably Anticipated Benefits Methodology and Hindsight Bias. The most fundamental vulnerability in the IRS's CSA position is the apparent use of hindsight-informed revenue projections in the computation of PBI's RAB share. PPC's cost-sharing ratios were determined prospectively each year on the basis of the best information available at the time, consistent with the express requirements of Treas. Reg. § 1.482-7(e)(2)(ii). PPC's projections were contemporaneously prepared by the Company's finance and commercial operations teams, reviewed by PPC's transfer pricing advisors at Crestfield & Associates, and documented in PPC's contemporaneous transfer pricing reports.
By contrast, Dr. Washburne's analysis appears to incorporate actual realized revenues in computing the RAB shares attributed to PBI for the examination years. The use of actual outcomes to determine what were supposed to be prospective, forward-looking projections is fundamentally inconsistent with the regulatory framework. The regulations require that RAB be measured on the basis of "reasonably anticipated" benefits — not actual, realized benefits. If the IRS were permitted to use hindsight to adjust cost-sharing ratios after the fact, the prospective requirement of the regulations would be rendered meaningless, as any deviation between projected and actual outcomes could be used as a basis for adjustment. This position finds support in Altera Corp. v. Commissioner, 145 T.C. 91 (2015), aff'd, 926 F.3d 1061 (9th Cir. 2019) (addressing the standards for cost-sharing arrangements), and the broader principle that the arm's-length standard evaluates transactions based on the information and circumstances available to the parties at the time of the transaction.
The Protest should include a detailed comparison of PPC's contemporaneous projections with the projections used by Dr. Washburne, identifying each point of divergence and demonstrating that the differences reflect the incorporation of hindsight data rather than legitimate methodological disagreements.
PCT Valuation Relevance and WACC Dispute. The IRS's attempt to bootstrap a 2012 PCT undervaluation — for a transaction that occurred outside the examination years — into adjustments of the 2017–2020 cost-sharing ratios is legally vulnerable on multiple grounds. As an initial matter, the PCT payment of $312 million was contemporaneously determined and documented using an income method/DCF approach with a WACC of 9.8%, which reflects the substantial development and regulatory risk associated with pharmaceutical-stage IP. The $312 million payment falls well within the arm's-length range established by Whitmore Valuation Group's independent DCF analysis, which places the arm's-length range for the PCT at $278 million to $361 million.
The IRS's use of a 7.2% WACC is the primary driver of the valuation gap between the IRS's $852 million PCT value and PPC's $312 million payment. The 260-basis-point differential in WACC accounts for the vast majority of the difference between the two valuations. We believe the IRS's 7.2% WACC is unreasonably low for several reasons:
• The pharmaceutical and biotechnology industry is characterized by high development risk, long development timelines, significant regulatory uncertainty, and high rates of clinical failure. Industry-standard cost-of-capital analyses for pharmaceutical companies consistently reflect these risks through higher discount rates. The 7.2% WACC used by Dr. Washburne is more consistent with the cost of capital for mature, diversified companies with stable cash flows — not for pharmaceutical IP with significant remaining development risk.
• Whitmore's analysis of comparable pharmaceutical and biotechnology company WACC estimates as of July 2012 yielded a range of 8.5% to 12.3%, with a median of 10.1%. PPC's 9.8% WACC falls comfortably within this range, while the IRS's 7.2% falls well below the low end.
• The specific compounds included in the PCT — primarily clinical-stage oncology compounds — carried substantial development risk at the time of the buy-in, including the risk of clinical trial failure, regulatory rejection, and competitive displacement. A discount rate that fails to account for these risks will systematically overvalue the IP and inflate the PCT amount.
Furthermore, even if the IRS could establish that the 2012 PCT was undervalued, the nexus between a 2012 undervaluation and 2017–2020 cost-sharing ratio adjustments is attenuated. The cost-sharing ratios for each year are determined independently based on the RAB shares for that year, and the appropriate remedy for a PCT undervaluation would be an adjustment to the PCT itself — not a wholesale recalibration of subsequent cost-sharing percentages. The IRS's theory conflates two distinct elements of the CSA framework: the buy-in payment for pre-existing IP and the ongoing cost-sharing payments for current R&D. These are separate analytical exercises under the regulations, and the IRS should not be permitted to use an alleged PCT undervaluation as a lever to increase cost-sharing ratios that are otherwise independently determined and arm's-length.
IRS's Proposed Percentages Are Facially Unreasonable. At the proposed cost-sharing percentages of 48.2% to 53.7%, PBI's cost-sharing ratio would significantly exceed the territory's share of actual realized revenue during the examination period. PBI's non-Americas territory accounted for approximately 38% to 43% of PPC's total pharmaceutical revenue during 2017–2020. By proposing cost-sharing ratios that materially exceed PBI's actual revenue share, the IRS's position implies that PBI's non-Americas territory was expected to generate a disproportionately large share of future benefits from the covered IP — a proposition that is inconsistent with the actual commercial trajectory of the products and with the best-available projections at the time the ratios were established.
This internal inconsistency is a significant vulnerability, as it suggests that the IRS's proposed ratios do not, in fact, reflect reasonably anticipated benefits as required by the regulations, but rather represent an arbitrary upward adjustment designed to shift income to the United States.
Whitmore CPM/TNMM Analysis. As an additional check on the reasonableness of the overall transfer pricing outcome, Whitmore Valuation Group performed a Comparable Profits Method / Transactional Net Margin Method ("CPM/TNMM") analysis of PBI's operating margins. The analysis identified 22 comparable distributors and IP-holding companies engaged in pharmaceutical commercialization activities. PBI's operating margins for each of the four examination years fell within the interquartile range of the 22 comparable companies, confirming that PBI's reported profitability is consistent with arm's-length results and that the overall transfer pricing outcome of the CSA is reasonable. This analysis provides a powerful cross-check against the IRS's proposed adjustments and should be prominently featured in the Protest.
B. Adjustment Category 2: Legacy IP Royalty Rate — $188,040,000
1. IRS Position
The second category of proposed adjustments relates to the royalty rate under PBI's license of pre-2012 vintage compounds from PPC. The IRS proposes increasing the royalty rate from 4.5% of net sales to 11.0% of net sales, based on the IRS's analysis of comparable uncontrolled transaction ("CUT") data from third-party pharmaceutical licensing agreements that the IRS contends support a higher arm's-length royalty rate for equivalent-stage, equivalent-therapeutic-area IP.
The proposed additional royalty income to PPC, and the corresponding additional royalty expense to PBI, for each examination year is calculated as follows:
The IRS's proposed 11.0% royalty rate represents a 144% increase over the existing 4.5% rate — from what PPC established as the arm's-length rate to a rate that is materially higher than the upper end of the interquartile range identified by Whitmore's CUT analysis. The IRS's position, if sustained, would have a significant impact on PPC's U.S. taxable income, notwithstanding that the legacy compound net sales are declining over the period, reflecting the natural lifecycle maturation of these products as they face generic competition, formulary changes, and loss of exclusivity in various non-Americas markets.
2. Legal Framework
The legal framework governing the royalty rate adjustments is set forth principally in the following regulatory provisions:
Treas. Reg. § 1.482-4 provides methods for determining the arm's-length consideration for the transfer of intangible property (or the use of intangible property through a license), including the comparable uncontrolled transaction method, the comparable profits method, and the profit split method.
Treas. Reg. § 1.482-4(c) sets forth the requirements for the CUT method, which determines the arm's-length royalty by reference to royalties charged in comparable uncontrolled transactions. The regulation requires a high degree of comparability between the controlled transaction and the uncontrolled comparables, taking into account the following factors: (i) the comparability of the intangible property involved, including its stage of development, uniqueness, and expected profitability; (ii) the comparability of the contractual terms, including territorial scope, exclusivity, duration, and risk allocation; (iii) the comparability of the economic conditions, including market size, competitive environment, and regulatory landscape; and (iv) the comparability of the property or services involved, including the nature of the products being commercialized.
Treas. Reg. § 1.482-1(c) sets forth the best method rule, which requires that the arm's-length result be determined using the method that, under the facts and circumstances of the case, provides the most reliable measure of an arm's-length result. The selection of a method and the application of that method must be based on a thorough analysis of the relevant facts and circumstances, and the method that provides the most reliable result will depend on the degree of comparability between the controlled and uncontrolled transactions and the quality of the data and assumptions used in the analysis.
3. Analysis of IRS Vulnerabilities — Royalty Rate Adjustments
Our analysis identifies several critical vulnerabilities in the IRS's royalty rate position, which collectively present a strong basis for contesting the proposed adjustment.
IRS CUT Selection Criteria Are Overly Aggressive. The IRS's CUT analysis relies on a set of comparable license agreements that, upon initial review, appear to involve early-stage, high-risk IP with significant remaining development costs, broader territorial grants, and materially different risk profiles from the PPC-PBI legacy compound license. The IRS's selected comparables appear to include agreements for compounds that were at earlier stages of clinical development (Phase II or early Phase III) at the time of licensing, with correspondingly higher royalty rates reflecting the licensor's contribution of high-value, high-risk IP with substantial upside potential. By contrast, PPC's legacy compounds are mature, late-lifecycle products with declining sales, limited remaining patent life, and comparatively modest growth prospects. The IRS's failure to adequately account for these differences in selecting and adjusting its CUT set is a fundamental methodological deficiency.
The IRS's proposed 11.0% royalty rate is far above the median and upper quartile of the arm's-length range established by Whitmore's more rigorous CUT analysis. Specifically, the 11.0% rate is approximately 420 basis points above the upper end of the interquartile range (6.8%) identified by Whitmore, placing it well outside the range of arm's-length results.
Whitmore CUT Analysis Results. Whitmore Valuation Group identified 14 comparable uncontrolled pharmaceutical license agreements through a systematic search and screening process that evaluated potential comparables for consistency with the characteristics of the PPC-PBI legacy compound license. The 14 agreements involved the licensing of mature, post-approval pharmaceutical compounds in therapeutic areas comparable to PPC's legacy portfolio, with territorial scope and risk allocations broadly consistent with the PPC-PBI arrangement. The results of Whitmore's CUT analysis are as follows:
• Interquartile range of royalty rates: 3.1% to 6.8%
• Median royalty rate: 4.4%
• PPC's contractual royalty rate: 4.5%
PPC's 4.5% royalty rate falls squarely within the arm's-length interquartile range and is essentially at the median of the 14 comparable agreements. This result powerfully supports the arm's-length character of PPC's royalty rate and demonstrates that the IRS's proposed 11.0% rate is a significant outlier relative to the market evidence.
Declining Sales Trajectory. The legacy compounds subject to the royalty arrangement are mature products with declining non-Americas net sales. Over the examination period, legacy compound net sales declined from $814.6 million in 2017 to $624.1 million in 2020, a cumulative decline of approximately 23.4%. In arm's-length negotiations, licensees of declining-revenue IP would be expected to demand lower royalty rates — not higher rates — to reflect the diminished economic value and remaining useful life of the licensed intangibles. The IRS's proposed upward adjustment from 4.5% to 11.0% is contrary to the economic logic of arm's-length licensing, where royalty rates are inversely correlated with the maturity and declining revenue trajectory of the licensed IP.
This argument is particularly compelling in the context of what arm's-length parties would actually negotiate. An unrelated licensee paying 4.5% on declining-revenue products would have no rational economic basis for agreeing to a rate of 11.0% — such a rate would dramatically reduce the licensee's profitability and, in many cases, render the licensed products commercially unviable in the non-Americas territory. The IRS's proposed rate implies a level of economic return to the licensor that is inconsistent with the economics of mature, declining pharmaceutical products.
Comparability Adjustments Not Made by the IRS. The NOPA and Dr. Washburne's supporting analysis do not appear to include sufficient comparability adjustments to account for the material differences between the IRS's selected CUT agreements and the PPC-PBI legacy compound license. Under Treas. Reg. § 1.482-4(c)(2), comparability adjustments are required when there are material differences between the controlled and uncontrolled transactions that could affect the royalty rate. At a minimum, the IRS's analysis should have adjusted for the following factors:
• Product lifecycle stage: The IRS's CUT agreements appear to involve earlier-stage, higher-risk compounds with greater upside potential, while PPC's legacy compounds are mature products with declining sales and limited remaining useful life.
• Territorial scope: Several of the IRS's CUT agreements appear to involve broader territorial grants (e.g., worldwide or worldwide-ex-U.S.) than the PPC-PBI license, which covers only non-Americas territories.
• Exclusivity terms: Differences in exclusivity provisions, co-promotion rights, and termination provisions can significantly affect royalty rates and must be accounted for in a CUT analysis.
• Risk allocation: The allocation of development risk, regulatory risk, and commercialization risk between licensor and licensee varies across the CUT agreements and differs from the risk allocation in the PPC-PBI arrangement, where PBI bears the full commercial risk for the non-Americas territory.
The absence of adequate comparability adjustments renders the IRS's CUT analysis unreliable under the best method rule and provides a strong basis for challenging the proposed royalty rate adjustment.
C. Correlative Offset — ($42,650,000)
The IRS exam team allowed a correlative offset of $42,650,000 against the aggregate proposed adjustments to avoid double-counting between the CSA cost-sharing adjustment and the royalty rate adjustment. The necessity for a correlative offset arises because certain R&D costs covered by the CSA relate to IP that is also the subject of the legacy royalty arrangement. Increasing both the cost-sharing ratio (which increases PBI's share of R&D costs, thereby increasing PPC's net income from the CSA) and the royalty rate (which increases PPC's royalty income from the legacy license) without an offset would attribute the same economic income to PPC twice — once through the higher cost-sharing ratio and again through the higher royalty rate.
The exam team's calculation of the $42,650,000 offset has not been fully explained in the NOPA, and the workpapers supporting the computation have not yet been provided. Our preliminary analysis suggests that the $42,650,000 correlative offset may be inadequate — that is, it may understate the true overlap between the two adjustment categories. The degree of overlap depends on the extent to which the legacy compounds' R&D costs are included in the CSA's qualified cost pool and the extent to which the value attributed to these compounds is reflected in both the cost-sharing ratios and the royalty rate. If the overlap is larger than the IRS has assumed, a greater offset should be allowed.
Under Treas. Reg. § 1.482-1(g), the IRS is required to take into account the effect of any allocation under § 482 on other related transactions. This provision supports the argument that the correlative offset must be computed with precision to avoid distortive results, and that PPC is entitled to request an increase in the offset if the exam team's computation is shown to be inadequate. We recommend developing a detailed analysis of the appropriate correlative adjustment under Treas. Reg. § 1.482-1(g) for inclusion in the Protest, with supporting calculations from Whitmore Valuation Group demonstrating the true extent of the overlap.
A separate research memorandum on correlative adjustments under Treas. Reg. § 1.482-1(g) will be developed for the Protest.
D. Summary of Net Proposed Adjustments by Year
The following table summarizes the proposed adjustments by year and category. The $42,650,000 correlative offset was allocated by the exam team across the four examination years; however, the precise annual allocation has not been specified in the NOPA. We have estimated the allocation below on a proportional basis, pending confirmation from the exam team or derivation from the NOPA workpapers.
Note: The correlative offset allocations shown above are estimated on a proportional basis and are subject to confirmation. The exact annual allocation will be confirmed with the exam team or derived from the NOPA workpapers when they are provided.
IV. Analysis of IRS Economic Substance Challenge
A. IRS's DEMPE Argument
In addition to the specific transfer pricing adjustments discussed in Section III, the IRS asserted, as a supplemental basis for its proposed adjustments, that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant. The IRS's argument is framed in the language of the OECD's DEMPE framework — Development, Enhancement, Maintenance, Protection, and Exploitation — which provides that the allocation of returns from intangible property should correspond to the functions performed, assets used, and risks assumed by the entities involved in the development and exploitation of the intangibles.
Specifically, the IRS contended that PPC's U.S.-based R&D personnel performed the overwhelming majority of development and enhancement activities related to the covered intangibles, and that PBI's role was limited to routine distribution and commercialization functions that do not warrant the level of IP-related returns that PBI currently earns. The IRS's position, if sustained, would support a recharacterization of PBI as a limited-risk distributor or commissionaire, entitled only to routine returns, rather than as a full-fledged IP owner and entrepreneur bearing market risk and earning residual returns.
The IRS did not present the economic substance argument as a standalone basis for adjustment, but rather as supplemental support for the CSA and royalty adjustments discussed above. Nevertheless, the argument has strategic significance because it could be deployed as leverage in settlement negotiations or at Appeals, and it must be addressed comprehensively in the Protest to prevent it from gaining traction.
B. Assessment of Vulnerabilities in the IRS's Economic Substance Argument
The IRS's economic substance argument is, in our assessment, the weakest of the three positions asserted in the NOPA. The factual record compiled during the examination — including C&H's functional analysis, Whitmore's economic analyses, and the testimony of PBI's employees — overwhelmingly supports PBI's substantive role in the DEMPE spectrum. The key facts supporting PBI's economic substance are as follows:
Personnel and Operational Build-Out. PBI employed 185 individuals as of fiscal year 2020, having grown from 52 employees at its establishment in 2012. The employee base includes personnel in regulatory affairs, medical affairs, commercial strategy, supply chain management, and administrative functions. These are substantive, high-value roles — not routine or ministerial positions — and their growth trajectory demonstrates PBI's progressive build-out of operational capability in Ireland over the period.
Board Governance and Decision-Making. PBI held a total of 42 board meetings in Dublin during the period 2017–2020, consisting of regular quarterly meetings and special sessions. The minutes of these meetings, which were produced in response to IDR No. 14, document key decisions made by PBI's board and management concerning pricing strategy across 68 country markets, market entry and withdrawal decisions, selection and management of distribution partners, regulatory submission strategies, and capital allocation. These decisions were made independently by PBI's leadership, with Managing Director Aidan Naughton exercising substantive decision-making authority.
Independent Pricing Authority. PBI made independent pricing decisions across 68 country markets in the EMEA and APAC regions. These pricing decisions were not dictated by PPC's U.S. headquarters; rather, they were made by PBI's commercial strategy team based on local market conditions, competitive dynamics, regulatory and reimbursement environments, and customer relationships. The independence of PBI's pricing authority is a critical indicator of substantive operational control and entrepreneurial risk-bearing.
Regulatory Expenditures. PBI incurred cumulative regulatory expenditures of approximately €47,200,000 during 2017–2020 for the preparation and filing of regulatory submissions across multiple non-Americas jurisdictions. These expenditures relate to PBI's performance of Maintenance, Protection, and Exploitation functions within the DEMPE framework, as regulatory compliance is essential to maintaining the value and marketability of the licensed intangibles in each country market.
Market Risk. PBI bore market risk for the non-Americas territories, including the risk of adverse regulatory outcomes (e.g., failure to obtain or maintain marketing authorization), unfavorable pricing and reimbursement decisions by government health authorities, currency fluctuations, competitive displacement, and changes in treatment guidelines. PBI's assumption of these risks is a key element of its role as an entrepreneur rather than a limited-risk entity.
Physical Presence and Infrastructure. PBI maintained approximately 18,000 square feet of office space at Sandyford Business Park in Dublin, providing a dedicated physical location for its management, regulatory, commercial, and administrative operations. PBI also maintained independent banking with Glenmore Bank Ireland plc, further demonstrating its operational independence from PPC's U.S. operations.
C&H Functional Analysis and Employee Interviews. C&H prepared a comprehensive functional analysis of PBI in October 2022, which was updated in March 2023 to reflect additional information gathered during the examination. The functional analysis documents PBI's personnel, functions, assets, and risks in detail and concludes that PBI performs substantive DEMPE functions — particularly in the areas of Maintenance, Protection, and Exploitation — that justify its role as IP owner and CSA participant. The functional analysis is supported by the results of 12 key PBI employee interviews conducted in August and September 2022, in which PBI personnel described their roles, responsibilities, and decision-making authority in their own words. The interview testimony corroborates PBI's independent decision-making and substantive operational functions.
Whitmore Economic Analyses. Whitmore Valuation Group's economic analyses — including the CPM/TNMM benchmarking analysis, the CUT analysis, and the DCF valuation of the PCT — are consistent with and support PBI's role as a substantive entity with genuine operational substance. PBI's reported profitability is consistent with that of comparable entities performing similar functions, bearing similar risks, and deploying similar assets, which is a strong indicator that PBI's transfer pricing results reflect its actual economic contribution.
In sum, the IRS's economic substance argument is contradicted by a comprehensive and well-documented factual record. However, the argument should not be dismissed or treated lightly. The IRS may deploy it as leverage in negotiations, and it could resonate with an Appeals officer or, in a worst-case scenario, with a court if the case proceeds to litigation. The Protest should address the economic substance argument comprehensively, presenting the full body of evidence supporting PBI's substantive role and directly rebutting the IRS's characterization of PBI as a routine distribution entity.
V. Analysis of Proposed Penalty — IRC § 6662(e)
A. IRS's Penalty Assertion
The IRS has asserted a 20% substantial valuation misstatement penalty under IRC § 6662(e) on the tax attributable to the $380,400,000 net § 482 allocation. Section 6662(e) imposes a 20% penalty on the portion of an underpayment of tax attributable to a substantial valuation misstatement under Chapter 1, which includes (among other things) any § 482 transfer pricing adjustment that exceeds the applicable thresholds. The NOPA's proposed penalty calculation is as follows:
Net proposed adjustment: $380,400,000 Corporate tax rate: 21% Tax attributable to adjustment: $380,400,000 × 21% = $79,884,000 20% penalty: $79,884,000 × 20% = $15,976,800 (approximately $15,977,000)
The IRS reserved, but did not assert, the 40% gross valuation misstatement penalty under IRC § 6662(h). The reservation of the 40% penalty preserves the IRS's ability to assert the higher penalty at a later stage, although the decision not to assert it in the NOPA may indicate that the exam team does not believe the threshold for a gross valuation misstatement has been met. However, this possibility should be monitored, and PPC's defense strategy should be prepared to address the 40% penalty in the event it is subsequently asserted.
B. Reasonable Cause and Penalty Protection Defense
PPC has a strong basis for contesting the proposed penalty under the reasonable-cause exception of IRC § 6662(e)(3)(B), which provides that no penalty shall be imposed under § 6662(e) with respect to any portion of an underpayment if the taxpayer establishes that there was reasonable cause for, and the taxpayer acted in good faith with respect to, such portion. In the transfer pricing context, the reasonable-cause standard is generally satisfied when the taxpayer maintains contemporaneous documentation that (i) meets the requirements of the applicable regulations and (ii) reflects a reasonable methodology that was applied in good faith.
PPC maintained contemporaneous transfer pricing documentation for all four examination tax years, which was prepared by Crestfield & Associates LLP (transfer pricing partner Susan Lam, CPA) in accordance with the standards of Treas. Reg. § 1.482-7 (for the CSA) and Treas. Reg. § 1.482-4 (for the legacy IP royalty). The documentation was prepared before the filing of each return and reflects a reasonable, good-faith effort to comply with the arm's-length standard. The specific elements supporting PPC's penalty defense include:
• The contemporaneous documentation was prepared by a qualified and experienced transfer pricing firm, using recognized methodologies and reliable data.
• The CSA cost-sharing ratios were determined using a RAB methodology that complies with the requirements of Treas. Reg. § 1.482-7(e)(2), based on prospective projections of future benefits.
• The 4.5% royalty rate for the legacy IP license was established through a CUT analysis that identified 14 comparable uncontrolled pharmaceutical license agreements, and the 4.5% rate falls at the median (4.4%) of the arm's-length interquartile range.
• The PCT was valued using an income method/DCF approach with a 9.8% WACC, which is within the range of industry-standard cost-of-capital estimates for pharmaceutical companies.
• PPC's transfer pricing positions are consistent across all four tax years and reflect a coherent, well-reasoned approach to intercompany pricing that is grounded in established transfer pricing principles.
Our assessment is that the penalty defense is strong. PPC's positions are reasonable and well-documented, even if the IRS disagrees with the specific numerical results. The penalty provisions are not intended to punish taxpayers who take reasonable positions in good faith; rather, they are designed to deter willful or reckless disregard of the arm's-length standard. PPC's conduct in this case falls well outside the scope of the penalty provisions. This argument will be a central element of the Protest and any subsequent Appeals proceeding, and we recommend asserting the reasonable-cause defense vigorously.
C. TCJA Rate Considerations on Penalty Computation
The NOPA appears to apply the 21% corporate tax rate uniformly to all four examination years in computing the tax attributable to the proposed adjustment and the corresponding penalty. However, for tax year 2017 (the period prior to the effective date of the Tax Cuts and Jobs Act of 2017, which reduced the corporate tax rate from 35% to 21% effective January 1, 2018), the applicable corporate tax rate is 35%, not 21%.
If the 35% rate applies to the 2017 adjustment, the tax and penalty allocable to that year would be materially higher than the NOPA reflects:
• Estimated 2017 net adjustment (from table above): approximately $90,280,000
• Tax at 35%: $90,280,000 × 35% = $31,598,000
• Tax at 21%: $90,280,000 × 21% = $18,958,800
• Difference in tax: $31,598,000 − $18,958,800 = $12,639,200
• Additional penalty at 20%: $12,639,200 × 20% = $2,527,840
The application of the correct rate to the 2017 adjustment should be confirmed with the exam team. If the IRS intends to apply the 35% rate to the 2017 adjustment, the overall proposed tax and penalty amounts will increase by the amounts indicated above. This issue does not affect the substantive merits of the adjustment, but it has a significant impact on the financial exposure calculation and should be factored into the FIN 48 analysis and settlement authority assessment.
VI. Assessment of IRS Economist's Methodology (Dr. Alan Washburne)
A. PCT Valuation — Income Method
As discussed in Section III.A above, Dr. Washburne valued the platform contribution transaction at $852,000,000 using an income method with a 7.2% weighted average cost of capital, compared to the $312,000,000 actually paid by PBI on July 1, 2012. The $540 million delta between the IRS's valuation and the actual PCT payment is driven primarily by two factors: (i) the difference in discount rates (7.2% versus 9.8%), and (ii) differences in the revenue projections used in the DCF models.
C&H's independent analysis, performed by Whitmore Valuation Group under the Kovel arrangement (reference 1018-00009-KV), used a 9.8% WACC and the Company's contemporaneous revenue projections to arrive at an arm's-length range of $278 million to $361 million for the PCT, with $312 million falling near the midpoint of this range. The 260-basis-point spread between the IRS's 7.2% WACC and PPC's 9.8% WACC is the key battleground in the PCT valuation dispute, as small differences in discount rates produce large differences in present-value calculations over the long projection horizons involved in pharmaceutical IP valuation.
As discussed in Section III.A.3 above, the IRS's 7.2% WACC is inconsistent with industry-standard cost-of-capital analyses for pharmaceutical and biotechnology companies, which reflect the significant development, regulatory, and commercial risks inherent in pharmaceutical IP. Whitmore's analysis of 18 publicly traded pharmaceutical and biotechnology companies as of July 2012 yielded a WACC range of 8.5% to 12.3%, with a median of 10.1%. The IRS's 7.2% rate falls well below the bottom of this range and is more consistent with the cost of capital for large-cap diversified industrials or utilities — not for pharmaceutical companies with significant pipeline risk.
B. Revenue Projections
Dr. Washburne applied higher revenue growth projections for PBI's non-Americas territory than those used in PPC's contemporaneous analyses. These higher projections had the effect of inflating the RAB shares attributed to PBI and correspondingly increasing the cost-sharing percentages proposed by the IRS. As noted in Section III.A.3, these projections appear to incorporate actual realized revenues — that is, the IRS economist appears to have looked at PBI's actual commercial performance during the examination years and used those outcomes as the basis for computing what PBI's RAB shares "should have been." This approach is fundamentally inconsistent with the prospective requirement of Treas. Reg. § 1.482-7(e)(2)(ii), which requires that reasonably anticipated benefits be measured on the basis of forward-looking projections using the best available information at the time the cost-sharing ratios are established.
The Protest should include a detailed, year-by-year comparison of PPC's contemporaneous revenue projections with the projections used by Dr. Washburne, identifying the specific data points where the IRS's projections diverge from PPC's projections and demonstrating that the divergences are attributable to the incorporation of hindsight data. This analysis should be prepared in coordination with Whitmore Valuation Group and presented in a format that clearly illustrates the improper use of actual outcomes in a prospective analysis.
C. CUT Selection for Royalty Rate
Dr. Washburne's CUT selection for the royalty rate adjustment relied on a set of comparable license agreements that, as discussed in Section III.B.3 above, involved earlier-stage IP with broader territorial scope and different risk profiles from the PPC-PBI legacy compound license. The comparability adjustments applied by Dr. Washburne to his selected CUTs w

MEMORANDUM

Record

Parties

Dates

Amounts